Cargando…

Glucocorticoid therapy and risk of bladder cancer

BACKGROUND: Use of immunosuppressive drugs post organ transplantation, and prolonged use of glucorticoids for other conditions have been associated with subsequent risk of certain malignancies, that is, skin cancers and lymphoma. There is evidence that the incidence of bladder cancer is also elevate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietrich, K, Schned, A, Fortuny, J, Heaney, J, Marsit, C, Kelsey, K T, Karagas, M R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768444/ https://www.ncbi.nlm.nih.gov/pubmed/19773763 http://dx.doi.org/10.1038/sj.bjc.6605314

Ejemplares similares

Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study
por: Fortuny, Joan, et al.
Publicado: (2007)

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer
por: Pridgeon, S W, et al.
Publicado: (2011)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Microbubble and ultrasound radioenhancement of bladder cancer
por: Tran, W T, et al.
Publicado: (2012)

The role of glucocorticoids in the induction of zinc-α(2)-glycoprotein expression in adipose tissue in cancer cachexia
por: Russell, S T, et al.
Publicado: (2005)

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
por: Nutt, J E, et al.
Publicado: (2007)

Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells
por: Adigbli, D K, et al.
Publicado: (2007)

Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets
por: Morera, Daley S, et al.
Publicado: (2017)

Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential
por: Rieger-Christ, K M, et al.
Publicado: (2005)

A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo
por: Sato, K, et al.
Publicado: (2006)

Phenformin as prophylaxis and therapy in breast cancer xenografts
por: Appleyard, M V C L, et al.
Publicado: (2012)

In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines
por: Adhim, Z, et al.
Publicado: (2011)

The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer
por: Hemdan, T, et al.
Publicado: (2014)

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study
por: Gunelli, R, et al.
Publicado: (2007)

Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy
por: Gash, K J, et al.
Publicado: (2017)

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells
por: Li, C, et al.
Publicado: (2005)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells
por: Stein, U, et al.
Publicado: (2012)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy
por: Miao, L, et al.
Publicado: (2014)

Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer
por: Tanaka, N, et al.
Publicado: (2011)

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression
por: Kashiwagi, Eiji, et al.
Publicado: (2018)

The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder
por: Hilmy, M, et al.
Publicado: (2006)

Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study
por: Martin, N K, et al.
Publicado: (2012)

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
por: Wattenberg, M M, et al.
Publicado: (2014)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer
por: Markovina, Stephanie, et al.
Publicado: (2018)

Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging
por: Vassileva, V, et al.
Publicado: (2008)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

Immune activation by combination human lymphokine-activated killer and dendritic cell therapy
por: West, E J, et al.
Publicado: (2011)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

In vitro evaluation of cancer-specific NF-κB-CEA enhancer–promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines
por: Guo, X, et al.
Publicado: (2007)

Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy
por: Duanmu, J, et al.
Publicado: (2011)

Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy
por: Keidar, M, et al.
Publicado: (2011)

Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment
por: Byrne, A T, et al.
Publicado: (2009)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

Peripheral neural cell sensitivity to mTHPC-mediated photodynamic therapy in a 3D in vitro model
por: Wright, K E, et al.
Publicado: (2009)

Low stromal Foxp3(+) regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer
por: McCoy, M J, et al.
Publicado: (2015)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f7ef7v7pjg5m935ngqv2a0sh95